- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01306799
To Learn How Bone Structure and Bone Mass Change After Long-term PPI Use (BE-CAST)
March 28, 2017 updated by: University of Pennsylvania
Effect of Chronic Proton Pump Inhibitor Therapy on Bone Mineral Density and Bone Structure in Mid to Late Adulthood
Patients with severe acid reflux and/or Barrett's esophagus are recommended to take Proton pump inhibitors (PPIs)indefinitely to prevent complications such as strictures or the development of a type of esophageal cancer.
Recently, some studies suggested that taking these medications on a long-term basis may affect the bone.
Therefore, it is important to learn whether these medications may lead to accelerated bone loss so that effective preventive measures can be developed for patients who require these medications for acid-related conditions.
Several studies reported that patients receiving PPIs for many years may have increased risk of hip fractures.
However, it is unclear whether this is because the PPIs cause reduced bone density or whether the increased risk of fractures has nothing to do with PPIs and is because patients who require PPIs have other illnesses that cause the increased fractures.
The purpose of the study is to learn how bone structure and bone mass change after long-term PPI use.
Study Overview
Status
Completed
Detailed Description
Proton pump inhibitors (PPIs) are among the most widely used medications.
It is becoming increasingly common for patients to take these potent acid suppressants on a long-term and continuous basis for erosive esophagitis, Barrett's esophagus and protection against nonsteroidal anti-inflammatory drug-related gastropathy.
PPI therapy leads to elevated serum gastrin levels and may impair the absorption of calcium and food-bound vitamin B12.
PPI-induced hypergastrinemia has a direct trophic effect on the parathyroid glands, leading to parathyroid hyperplasia, increased parathyroid hormone secretion and bone loss.
Furthermore, both calcium malabsorption and vitamin B12 deficiency are associated with reduced bone mineral density (BMD) and increased osteoporotic fracture risk.
Consistent with these data, recent studies revealed a positive association between PPI therapy and the risk of osteoporotic fractures.
Peripheral quantitative computed tomography (pQCT) can provide a three-dimensional structural analysis of trabecular and cortical volumetric BMD (vBMD) and dimensions.
These data are imperative for a valid assessment of the effect of chronic PPI therapy on bone strength.
The investigators hypothesize that PPI therapy leads to decreased cortical and trabecular vBMD, cortical dimensions and bone strength.
Study Type
Observational
Enrollment (Actual)
106
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
- Patients who either are starting or have been receiving long-term continuous PPI therapy for erosive esophagitis or Barrett's esophagus diagnosed within the past three years.
- Patients who are starting PPI therapy for gastroesophageal reflux disease (GERD) and have shown a subjective improvement in symptoms within 4 weeks of starting therapy. This improvement will be assessed either through documentation in their medical record or through telephone interview with permission from their physician.
- Patients who are starting PPI therapy for ulcer prophylaxis in a setting of chronic aspirin use.
- Patients who are starting PPI therapy for extraesophageal manifestations of GERD.
Description
Inclusion Criteria:
- women between 50 to 75 years old
- men between 40 to 75 years old
- Barrett's esophagus and Erosive esophagitis diagnosed within the past three years, GERD or Acid Reflux, taking chronic aspirin
- Starting long-term PPI therapy or currently on long-term PPI therapy
Exclusion Criteria:
- Pre-menopausal women
- men under 40 years old
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Barrett's Esophagus, Erosive Esophagitis, GERD
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Volumetric bone mineral density as measured by pQCT
Time Frame: 3 years
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
measure PTH levels at each study visit
Time Frame: 3 years
|
monitor change in PTH levels because long-term PPI therapy may have an affect on parathyroid glands, increasing parathyroid hormone (PTH) secretion.
|
3 years
|
measure vitamin B12 levels at each study visit
Time Frame: 3 years
|
low B12 levels have been associated with reduced bone mineral density (BMD) as well osteoporotic fracture risk
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Yu-Xiao Yang, MD, MSCE, University of Pennsylvania
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2010
Primary Completion (Actual)
April 1, 2015
Study Completion (Actual)
April 1, 2015
Study Registration Dates
First Submitted
February 17, 2011
First Submitted That Met QC Criteria
March 1, 2011
First Posted (Estimate)
March 2, 2011
Study Record Updates
Last Update Posted (Actual)
March 30, 2017
Last Update Submitted That Met QC Criteria
March 28, 2017
Last Verified
March 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 810599
- 1R01AR057102-01 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Barrett's Esophagus
-
Northwell HealthMayo Clinic; NinePoint MedicalCompletedBarrett's Esophagus Without Dysplasia | Barrett's Esophagus With Dysplasia | Barrett's Esophagus With Low Grade Dysplasia | Barrett's Esophagus With High Grade Dysplasia | Barrett's Esophagus With Dysplasia, UnspecifiedUnited States
-
Case Comprehensive Cancer CenterCompletedShort Segment Barrett's Esophagus | Long Segment Barrett's EsophagusUnited States
-
The Guthrie ClinicActive, not recruiting
-
Interscope, Inc.RecruitingBarrett's Esophagus With DysplasiaUnited States, Sweden, United Kingdom
-
Mayo ClinicCompletedBarrett's Esophagus With DysplasiaUnited States
-
Massachusetts General HospitalEnrolling by invitationBarrett Esophagus | Barrett's Esophagus Without Dysplasia | Barretts Esophagus With DysplasiaUnited States
-
Lucid Diagnostics, Inc.CompletedBarrett Esophagus | Esophageal Adenocarcinoma | Barrett's Esophagus Without Dysplasia | Barretts Esophagus With DysplasiaUnited States, Spain
-
University of CambridgeUniversity of NottinghamRecruitingBarrett's OesophagusUnited Kingdom
-
Johns Hopkins UniversityAmerican Society for Gastrointestinal Endoscopy; Pentax Medical CorporationCompletedBarrett's Esophagus, Esophageal Intraepithelial NeoplasiaUnited States, Germany
-
Mayo ClinicFred Hutchinson Cancer CenterCompletedBarrett's Esophagus With High Grade Dsyplasia | Early Esophageal CancerUnited States